• Call: +44-2038074155  |  Mail: Sales@brandessenceresearch.com  | | | | |

Bispecific Antibody Market Size, Share & Trends Analysis Report By Product Type (Blinatumab, Catumaxomab, Duligotumab), By Application (Infectious Diseases, Viral Infections, Cancer Diagnostics, Gene Therapy, Signaling Pathways, Bacterial Infections, Tumor Angiogenesis, Others), Region, And Segment Forecasts, 2021 - 2027

  • Report ID: BMRC 1129 | Number of pages: 200 | Published Date: May 2021

    Published | Category: Healthcare | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Bispecific Antibody Market Size, Share & Trends Analysis Report By Product Type (Blinatumab, Catumaxomab, Duligotumab), By Application (Infectious Diseases, Viral Infections, Cancer Diagnostics, Gene Therapy, Signaling Pathways, Bacterial Infections, Tumor Angiogenesis, Others), Region, And Segment Forecasts, 2021 - 2027 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

Global Bispecific Antibody Market is valued at USD 489.7 Million in 2020 and expected to reach USD 810.4 Million by 2027 with the CAGR of 6.5% over the forecast period.

Global Bispecific Antibody Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Increasing numbers of patients associated with infectious diseases and cancers as well as growing numbers of Covid-19 patients are contributing in the market growth.              

Scope of Global Bispecific Antibody Market Report

Bispecific antibody is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Most of the bispecific antibodies are being developed for the treatment of multiple cancers followed by infectious disease, CNS disorders, inflammatory and autoimmune disorders. The benefits of bispecific antibodies over monoclonal therapeutics are due to their higher binding avidity to targets, which can interact with more than one surface antigen and boosted cytotoxic effects. It is because of the direct recruitment of effector cells to the site of the disease or in tumorigenic conditions. Bispecific antibodies may be used to improve clinical efficacy by targeting two disease mechanisms for the treatment of complex human diseases in a single agent. Bispecific antibodies also hold promise for certain therapeutic applications difficult to achieve by single-targeting monospecific antibodies, such as immune cell retargeting, site-specific targeting, enabling therapeutics to cross the blood–brain barrier, and unique receptor modulation.

Bispecific antibodies (bsAbs) combine the specificities of two antibodies to target separate antigens or epitopes at the same time. BsAbs with 'two target' functionality can bind to several receptors or ligands on the surface of cells. BsAbs can also bring targets close together, either to help build protein complexes on one cell or to cause cell-to-cell contact. In 2009, the first bsAb was approved. Another bsAb was approved in December 2014, and several others are being tested in clinical studies. Researchers have developed a way to modify the size, valency, flexibility, half-life, and bio distribution of bsAb to meet the desired target–product profile in the creation of bsAb for therapeutic and diagnostic purposes. The current focus of bsAb clinical development is on two key areas: cancer therapy and inflammatory illnesses. The main goal is to target many targets implicated in pathophysiological processes at the same time in order to improve treatment efficacy. The global demand for bispecific antibodies is being reinforced by emerging novel strategies and application in various disease therapies along other aspects. Furthermore, the use of bispecific antibody assay is being used in the detection of SARS-CoV. This assay was superior to the traditional monoclonal ELISA-based assay. The use of bispecific antibodies in the detection of Covid-19 infections can propel the bispecific antibodies market forward.

During Covid-19 pandemic, people were obliged to stay indoors, and as a result of the lockout, medical treatments and facilities, as well as diagnostic procedures and procedures for infectious diseases and cancers, were delayed, which has shown a decline impact on the bispecific antibody market growth. However, according to Cold Spring Harbor Laboratory, the use of bispecific antibodies to neutralize emerging SARS-CoV-2 variants is being investigated. The use of bispecific antibodies in the neutralization of Covid-19 infections has the potential to move the market for bispecific antibodies forward. The market will gain pace again with the recovery from this Covid-19 situation.

The regions covered in this Global Bispecific Antibody Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, market of Global Bispecific Antibody is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc. 

Top Companies:

Key Players for Global Bispecific Antibody Market Report–

Some key players for Global Bispecific Antibody Market are Oncomed Pharmaceuticals, Abbvie, Bayer AG, Janseen Biotech, Fabion Pharmaceuticals, Novartis AG, Pfizer Inc., ImmunGene, Inc., Celgene, Amgen Inc., Immunocore Limited, Merck & Co., Inc., Paktis Antibody Services GmBH, Ganymed Pharmaceuticals, Dow Pharmaceutical Solutions, and F. Hoffmann-La Roche AG others.

Bispecific Antibody

News

For Agenus' Bispecific Antibody Development, BMS will Pay Up to $1.56 Billion.

On May 20th, 2021; Bristol Myers Squibb (BMS) has signed an exclusive licencing agreement with Agenus to get access to the company's preclinical anti-TIGIT asset. Agenus' AGEN1777 is a preclinical antibody candidate that blocks TIGIT and a second undisclosed target to boost anti-tumor activity by targeting important inhibitory receptors present on T and NK cells. This method has shown promise in preclinical research in tumor models where anti-PD-1 or anti-TIGIT monospecific antibodies alone are ineffective. As part of the agreement, BMS will pay Agenus $200 million upfront and up to $1.36 billion in development, regulatory, and commercial milestones, as well as tiered double-digit royalties on net product sales. Agenus will maintain the option to conduct clinical studies under the development plan and to perform combination studies with some of its other pipeline assets under the terms of the agreement. AGEN1777's distinct mechanism of action has the promise of significant anti-tumor efficacy, accelerating our clinical TIGIT plan to help more cancer patients with unmet needs. In the second quarter of this year, Agenus plans to submit an investigational new drug application (IND) for AGEN1777 to the US Food and Drug Administration (FDA). Meanwhile, BMS will continue to promote bispecific antibody research and development in immuno-oncology for ‘high priority tumor indications such as non-small cell lung cancer (NSCLC).

Increasing Numbers of Patients Associated with Infectious Diseases and Cancers as Well as Growing Numbers of Covid-19 Patients are the Major Factors Driving the Market Growth

The growing demand for bispecific antibodies for the treatment of infectious diseases, cancer tumors, bacterial infections, and cancer diagnostics is one of the major factors fostering the growth of bispecific antibody market. Since the numbers of cancer patients and infectious diseases are growing, the requirement to cure the patients has increased. For instance, according to the Journal of Hematology & Oncology, several bispecific antibody cytokines have been identified as important mediators in the development of inflammatory and autoimmune disorders. As a result, blocking these cytokines has therapeutic promise in the treatment of inflammatory and infectious diseases. Inhibition of TNF- has significant therapeutic effects in the treatment of psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, juvenile arthritis, and a variety of other disorders. According to WHO, Infectious diseases are responsible for 9.5 million fatalities each year, which is posing a major socioeconomic cost on society. Surveillance methods are used by global healthcare systems to control the spread of infectious diseases, which are dependent on early diagnosis. And, 18.1 million persons were diagnosed with cancer worldwide in 2018, with 9.6 million deaths. Lung cancer is the most commonly diagnosed cancer (11.6%), closely related to female breast cancer (11.6%) and colorectal tumors (10.2%). Lung cancer is the leading cause of cancer death (18.4% of all fatalities), followed by colorectal cancer (9.2%), and stomach cancer (8.2%).

In addition, rising number of Covid-19 cases are also supplementing the market growth. The bispecific antibodies can be used to treat the Covid-19 patients for improving the antibody potentials. For instance; according to Taylor and Francis mAbs Journal, SARS-CoV-2 neutralizing bispecific antibodies have been found in large numbers, with the majority of them directly blocking the viral Spike receptor-binding domain (RBD) from binding to angiotensin-converting enzyme. II (ACE2). Fabs are antigen-binding fragments produced by phage display that bind RBD but do not block ACE2 or neutralize the virus. A 25-fold improvement in neutralizing SARS-CoV-2 when these non-neutralizing Fabs were assembled into bispecific VH/Fab immunoglobulin with a neutralizing VH domain compared to the mono-specific bi-valent VH-Fc alone or the cocktail of the VH -Fc and Immunoglobulin was observed. A promising and rapid engineering technique to increase the efficacy of SARS-CoV-2 antibodies is to create a bispecific antibody that includes both neutralizing and non-neutralizing epitopes on Spike-RBD. According to the World Health Organization (WHO), new COVID-19 cases increased by almost 5.2 million in the preceding week, surpassing the previous peak of early January 2021. With nearly 83,000 new deaths registered the number of new deaths climbed by 8% from the previous week.

However, the high cost of the drugs and R & D investment may hamper the growth of the global bispecific antibody market. In spite of that, increasing research and development activities in this field may create more opportunities for the further growth of the market.

Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2027
Market Size in 2020: USD 489.7 Million 
Base year considered 2020
Forecast Period CAGR %:

6.50 %

Market Size Expected in 2027: USD 810.4 Million 
Tables, Charts & Figures: 175
Pages 200
Key Players/Companies Oncomed Pharmaceuticals, Abbvie, Bayer AG, Janseen Biotech, Fabion Pharmaceuticals, Novartis AG, Pfizer Inc., ImmunGene, Inc., Celgene, Amgen Inc., Immunocore Limited, Merck & Co., Inc., Paktis Antibody Services GmBH, Ganymed Pharmaceuticals, Dow Pharmaceutical Solutions, and F. Hoffmann-La Roche AG others
Segments Covered By Product Type, By Application
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global Bispecific Antibody Market Report–

  • Global Bispecific Antibody Market report covers in depth historical and forecast analysis.
  • Global Bispecific Antibody Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
  • Global Bispecific Antibody Market report helps to identify opportunities in market place.
  • Global Bispecific Antibody Market report covers extensive analysis of emerging trends and competitive landscape.

Segmentation Analysis:

Global Bispecific Antibody Market is segmented on the basis of product types, applications, and region & country level. Based upon product type, bispecific antibody market is classified into blinatumab, catumaxomab and duligotumab. Based upon applications, the market is divided into BsMAb for cancer diagnostic, BsMAb for diagnosis of bacterial & infectious diseases, BsAbs blocking signaling pathways, BsAbs targeting tumor angiogenesis, specific delivery of effector compounds to targets, bispecific antibodies and gene therapy.

Global Bispecific Antibody Market Segmentation

By Product Type:

  • Blinatumab
  • Catumaxomab
  • Duligotumab

By Application:

  • Infectious Diseases
  • Viral Infections
  • Cancer Diagnostics
  • Gene Therapy
  • Signaling Pathways
  • Bacterial Infections
  • Tumor Angiogenesis
  • Others

Global Bispecific Antibody Market By Regional & Country Level:

North America is Expected Dominate the Global Bispecific Antibody Market.

North America is expected to dominate the global bispecific antibody market owing to the increasing number of cancer patients and highly developed healthcare infrastructure in this region. According to the Journal of Technology in Cancer Research & Treatment, melanoma was responsible for roughly 92% of new occurrences of skin cancer and 69% of skin cancer-related deaths in the United States in 2018. Leukemia and gastrointestinal malignancies are included in the second group. Europe is expected to witness a significant growth in this market owing to the increasing numbers cancer patients, rising geriatric population, and growing investment in this field. The bispecific antibodies are an efficient way to treat the diseases by aiding immunity improvement. Asia Pacific is expected to witness a fastest growth in this market due to the improving healthcare infrastructure and increasing research & development activities in this region.

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia

Latin America

  • Brazil
  • Mexico


Frequently Asked Questions (FAQ) :
Global Bispecific Antibody Market is valued at USD 489.7 Million in 2020 and expected to reach USD 810.4 Million by 2027 with the CAGR of 6.5% over the forecast period.
North America is expected to dominate the global bispecific antibody market due to growing incidences of cancer such as lung cancer, cervical cancer, breast cancer, and prostate cancer
Increasing Research and Development for Novel Bispecific Antibodies is one of the Major Factors Driving the Global Bispecific Antibodies Market.
Aspen Holdings Bayer AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Daiichi Sankyo Company Limited GlaxoSmithKline plc. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) Pfizer, Inc Portola Pharmaceuticals, Inc. Sanofi S.A. Others



Interested in this report?

Bispecific Antibody Market Size 2021 and Analysis 2019-2025

report cover

Bispecific Antibody Market Size, Share & Trends Analysis Report By Product Type (Blinatumab, Catumaxomab, Duligotumab), By Application (Infectious Diseases, Viral Infections, Cancer Diagnostics, Gene Therapy, Signaling Pathways, Bacterial Infections, Tumor Angiogenesis, Others), Region, And Segment Forecasts, 2021 - 2027

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.

    Pricing



+44-1173181773
vishal@brandessenceresearch.com


Looking for Regional Reports?